PROSPECTIVE , RANDOMIZED PHASE II STUDY 
COMPARING TWO ELUTION RATES OF GLA[LOCATION_006]OS 
TRAVOPROST INTRAOCULAR IMPLANTS TO 
TIMOLOL MALEATE OPHTHALMIC SOLUTION , 
USP,  0.5%
PROTOCOL #GC-009 
DOCUMENT CONTROL # AND REVISION #: CR-0412-2015  REV 2 
DATE:  SEPTEMBER 16, 2016 
Sponsor: 
GLA[LOCATION_006]OS CORPORATION  
229 Avenida Fabricante │ San Clemente, CA  [ZIP_CODE] │ ([PHONE_216] 
[STUDY_ID_REMOVED]
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175720] Articles ...............................................................................................15 
6.1.2. Control Articles ..........................................................................................17 
6.1.3. Other Articles .............................................................................................17 
7. METHODS  ...........................................................................................................18 7.1.  SUBJECTS ..........................................................................................................18 7.2.  ELIGIBILITY REQUIREMENTS ......................................................................18 
7.2.1. Inclusion Criteria .......................................................................................18 
[IP_ADDRESS]. Screening Inclusion Criteria ............................................................18 
[IP_ADDRESS]. Baseline Inclusion Criteria ..............................................................20 
7.2.2. Exclusion Criteria ......................................................................................20 
[IP_ADDRESS]. Screening Exclusion Criteria ...........................................................20 
[IP_ADDRESS]. Baseline Exclusion Criteria .............................................................[ADDRESS_175721] Exit Prior to Study Completion ..................................23 
[IP_ADDRESS]. Prior to Randomization ...................................................................23 
[IP_ADDRESS]. After Randomization .......................................................................24 
[IP_ADDRESS].1. Subject Lost to Follow-Up .......................................................[ADDRESS_175722] Compliance .................................................24 
7.3.3. Enrollment..................................................................................................25 
7.3.4. Screening Phase .........................................................................................25 
[IP_ADDRESS]. Visit 1 (Screening) ...........................................................................25 
[IP_ADDRESS]. Visit 2 (Baseline) .............................................................................26 
7.3.5. Treatment Phase .........................................................................................27 
[IP_ADDRESS]. Visit 3 (Operative Exam) ................................................................27 
[IP_ADDRESS]. Visit 4 (Day 1-2 Exam) ...................................................................28 
[IP_ADDRESS]. Visit 5 (Week 1-2 Exam) .................................................................29 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175723] Demographic and Ba seline Characteristics ..................................47 
9.6.4. Efficacy Analyses ......................................................................................48 
[IP_ADDRESS].Primary Efficacy Analysis ...................................................................48 
[IP_ADDRESS].Sensitivity Analysis .............................................................................48 [IP_ADDRESS].Analysis of Covariates .........................................................................49 [IP_ADDRESS].Subgroup Analysis ...............................................................................49 [IP_ADDRESS].Exploratory Analyses ...........................................................................49 
9.6.5. Safety Analyses ..........................................................................................49 
[IP_ADDRESS].Study Drug Exposure ...........................................................................50 [IP_ADDRESS].Surgical Complications ........................................................................50 [IP_ADDRESS].Adverse Events ....................................................................................50 [IP_ADDRESS].Best Spectacle Corrected Visual Acuity (BSCVA) .............................[ADDRESS_175724] or Timolol ......................................52 
10.3.  Serious Adverse Event .......................................................................................52 
10.4.  Unexpected Adverse Event ................................................................................53 
10.5.  Non-Serious Adverse Event ...............................................................................54 
10.6.  Intercurrent Events Prior to Randomization ......................................................54 
10.7. Follow-up After Adverse Events ........................................................................54 
11. MAINTAINING THE MASK ..................................................................................54 
12. INFORMED CONSENT ..........................................................................................55 
13. INSTITUTIONAL REVIEW ....................................................................................55 
14. CONFIDENTIALITY/PUBLICATION OF THE STUDY ......................................[ADDRESS_175725] Retention ...............................................................................................57 
17. BIBLIOGRAPHY ..................................................................................................58 
18. APPENDIX A – SCHEDULE OF VISITS AND ASSESSMENTS ........................59 
19. APPENDIX B – OBLIGATIONS OF INVESTIGATORS......................................60 
20. APPENDIX C – ELEMENTS OF INFORMED CONSENT ...................................61 
21. APPENDIX D - DECLARATION OF HELSINKI..................................................63 
22. APPENDIX E – GLA[LOCATION_006]OS TRAVOPROST INTRAOCULAR IMPLANT 
SURGICAL INSTRUCTIONS ..........................................................................................68 23. APPENDIX F –1 TRAVATAN PACKAGE  INSERT AND APPENDIX F-2 
TIMOLOL PACKAGE INSERT………………………………………………………...70 24. APPENDIX G – ARTIFICIAL TEARS PACKAGE INSERT ................................81 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 5 of 91 
25. APPENDIX H – ASSIGNING SUBJECT NUMBERS AND KITS ........................82 
26. APPENDIX I – PROCEDURES FOR EXAMINATIONS ......................................[ADDRESS_175726] Sp ectacle Corrected Visual Acuity 
(ETDRS)   .................................................................................................83 
26.3.  Pachymetry…… ................................................................................................84 
26.4.  Gonioscopy…… ................................................................................................84 
26.5.  Slit-lamp Biomicroscopy ...................................................................................84 
26.6.  Intraocular Pressure (IOP) .................................................................................[ADDRESS_175727] IOP Measurement .......................................................................86 
26.6.2. Diurnal IOP Measurement .........................................................................86 
26.7.  Ophthalmoscopy ................................................................................................86 
26.8.  Visual Field ….. .................................................................................................87 
26.9.  Specular Microscopy .........................................................................................87 
26.10.  Conjunctival Hyperemia, Iris, Eyel ash and Periorbital Assessments and 
Photographs and Blood Sampling ... ................................................................88 
26.10.1. Conjunctival Hyperemia ......................................................................88 
26.10.2. Iris (Color) Assessment ........................................................................88 
26.10.3. Eyelash (Length and Density) Assessment ..........................................89 
26.10.4. Periorbital Assessment .........................................................................89 
26.10.5. Blood Sampling ...................................................................................89 
 
 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 7 of 91 
 
Objective: 
To compare the safety and initial efficacy of intraocular implants containing travoprost at 
two different elution rates versus Timolo l Maleate Ophthalmic Solution, USP, 0.5% 
(timolol) in reducing elevated intraocular pre ssure in subjects with  open-angle glaucoma 
(OAG) or ocular hypertension (OHT).   
 
Clinical Hypotheses: 
‐ Intraocular implants containing travoprost are at least as effective as timolol in 
achieving lowered intraocular pressure  (IOP) in subjects with open-angle 
glaucoma (OAG) or ocular hypertension (OHT) 
‐ Intraocular implants containing travoprost are well-tolerated 
 
Study Population: Approximately [ADDRESS_175728] complete a required medication washout/waiting period. At the Baseline visit, all subjects 
must have mean diurnal IOP of  in the study eye, and meet all other entry 
criteria. 
 
Structure: parallel groups 
 
Multicenter: Yes  
Masking: 
‐ Observer-masked (IOP readings, assessments of 
symptomatology) 
‐ Subject-masked 
 
Method of Subject Assignment: After the 4:00 pm IOP measurement at Visi t 2 (Baseline), qualified subjects will be 
scheduled to undergo treatment with the G2 TR-  implant, the G2TR-  implant, or 
timolol in a ratio of 1:1:1.  Randomization: Yes 
 
Estimated Total Sample Size: Approximately 150 subjects  
Statistical Rationale Provided: Not Applicable 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 9 of 91 
 
 Study Variables and Statistical Analysis: 
Efficacy Variable 
The primary efficacy variable will be the IOP at [ADDRESS_175729] spec tacle-corrected visual acuity, biomicroscopy 
findings, gonioscopy findings, ophthalmoscopy findings (including cup/disc ratio), 
pachymetry, visual field test evaluation and endothelial cell parameters, will be summarized. In addition, changes from base line in conjunctival hyperemia, periorbital 
measurements, iris (color) and eyelashes (d ensity and length) will be analyzed, if 
feasible.  Blood plasma testing will be performed to assess systemic exposur e to the implant study 
medication (travoprost free acid).   Analysis Populations 
Refer to Statistical Analysis Section (Section 9).   
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175730] OF ABBREVIATIONS A ND DEFINITION OF TERMS 
Abbreviation/Term Definition 
AA Alpha agonist 
AREDs Alpha agonist 
AE Adverse event 
BAK Benzalkonium chloride 
BB Beta blocker 
BSCVA Best spectacle corrected visual acuity 
CAI Carbonic anhydrase inhibitor 
CRF Case report form 
ECD Endothelial cell density 
ETDRS Early Treatment of Diabetic Retinopathy Study 
FDA Food and Drug Administration 
GCP Good clinical practice 
ICH International Conference on Harmonization 
IOP Intraocular pressure 
IRB Institutional Review Board 
ITT Intent-to-treat 
LogMAR Logarithm of the minimum angle of resolution 
MA Medical Affairs 
MedDRA Medical Dictionary  for Regulatory Activities 
mmHg Millimeters of mercury 
OAG Open-angle glaucoma 
OHT Ocular hypertension 
OTC Over the counter 
PG Prostaglandin 
PVG Pharmacovigilance 
SAE Serious adverse event 
SOC System organ class 
TEAC Treatment Emergent Adverse Event 
VF Visual field 
 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175731] on a patient's vision a nd quality of life. Reducing intraocular 
pressure is the only proven treatment for glaucoma.  
 
Treatment for open-angle glaucoma (OAG) has started traditionally with topi[INVESTIGATOR_11228].  Devel opment of more effective medications has 
increased the popularity of this  approaches as initial tr eatment compared to more 
invasive incisional or drainage device  surgery. Furthermore, the more benign 
medication treatments preserve the ocular tissues in the event that more invasive 
surgical approaches are eventually required. 
 
The various topi[INVESTIGATOR_152590], β-
adrenergic receptor antagonists ( β-blockers), carbonic anhydra se inhibitors (CAIs), α-
adrenergic receptor agonists ( α-agonists), and prostagla ndin analogues (PGs). The 
PGs are a class of ocular hypotensive agen ts that have been proven effective in 
lowering IOP in subjects with  OAG or OHT. Advantages of this class of medications 
over other classes is that the system ic side effects associated with α-agonists (e.g., dry 
mouth, drowsiness) and β-blockers (e.g., depression, fa tigue, bradycardia) do not 
appear to be associated with PGs.  Furt hermore, the ocular si de effects typi[INVESTIGATOR_11230] a-agonists (e.g., allergic reactions), and chol inergic agents (e.g., 
reduced vision), do not seem to ma nifest with the use of PGs. 
 
In spi[INVESTIGATOR_152591], PGs have been shown to be associated with 
side effects such as ocular hyperemia,  iris hyperchromia, periorbital atrophy, 
increased eyelash growth, general ocul ar surface discomfort and headache.
1-[ADDRESS_175732] Intraocular Implant: Model G2TR-  
and Model G2TR- . The implants are iden tical except that they are designed to 
elute travoprost at two differe nt elution rates. For the purposes of this protocol, Model 
G2TR-  is the high elution rate implan t and Model G2TR-  is the low elution 
rate implant).  
 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 27 of 91 
7.3.5.  Treatment Phase 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 28 of 91 
[IP_ADDRESS]. Visit 4 (Day 1-2 Exam, 1-2 days) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 29 of 91 
[IP_ADDRESS]. Visit 5 (Week 1-2 Exam, 10 days ± 3) 
 
[IP_ADDRESS]. Visit 6 (Week 4 Exam, 28 days ± 3) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 30 of 91 
 
[IP_ADDRESS]. Visit 7 (Week 6 Exam, 42 days ± 3) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 31 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 32 of 91 
7 3 5 7  Visit 9 (Month 6 Exam  182 days ± 14) 
[IP_ADDRESS]. Visit 10 (Month 9 Exam, 274 days ± 14) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 33 of 91 
 
 
 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 34 of 91 
[IP_ADDRESS]. Visit 12 (Month 15 Exam, 455 days ± 30) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 35 of 91 
 
[IP_ADDRESS]. Visit 13 (Month 18 Exam, 547 days ± 30) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 36 of 91 
 
7 3 5 12  Visit 14 (Month 21 Exam  637 days ± 30) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 38 of 91 
[IP_ADDRESS]. Visit 17 (Month 30 Exam, 910 days ± 60) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 39 of 91 
 
 
[IP_ADDRESS]. Visit 18 (Month 33 Exam, 1000 days ± 60) 
 
 
[IP_ADDRESS]. Visit 19 (Month 36 Exam, 1095 days ± 60) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 50 of 91 
number of ETDRS will be summarized us ing the statistics for the continuous 
variables. 
 
Additionally, the number and per centage of subjects will be  summarized for each of 
the three treatment groups based on the following VA categories: 
 
 
  
  
  
  
  
  
 
10. ADVERSE EVENTS
 
Adverse events will be monitored throughout  the course of the study, and reported 
on an adverse event (AE) form . Any significant change in a 
subject's condition from baseline, re gardless of causality, is to be 
considered an adverse event, unless the change is determined to be a continuation of a pre-existing c ondition that is documented in the 
subject's medical history. However, a clinically significant increase in frequency or worsening in seve rity of a pre-existing condition 
may indicate an adverse event. In addition, a clinical ly significant 
laboratory finding may also indicate an adverse event.  Lack of 
efficacy of the study treatment for the condition being investigated 
is not an adverse event. Subjects should be asked using a general, 
non-direct question if th ere has been any change  in how they feel 
from the previous visit (e.g., "H ow have you felt since the last 
visit?"). Direct questioning and examination should then be 
performed as appropriate.  If an adverse event occurs, then an AE form must be completed includi ng a description of the event, 
seriousness, severity, onset a nd duration, action taken, outcome, 
and relationship to study medication.   A separate AE Form must be 
completed for each adverse event. All items on the AE form must be completed. 
 
If an adverse event is ongoi ng at the time of study exit, th en the investigator should 
perform reasonable follow-up efforts as n ecessary (e.g., telephone contact, post-study 
office visit) to determine the outcome of the event. 
 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 55 of 91 
 
15. STATEMENT OF COMPLIANCE 
This study will be conducted in compliance with the protocol, good clinical practices 
(GCP), International Conference on Harmoniza tion (ICH) guidelines, the Declaration of 
Helsinki, and applicable regulatory requirements.  16. RECORD KEEPI[INVESTIGATOR_1645] 16.1.  Source Documents 
The clinical investigator must maintain detailed source documents on all study subjects. Source documents include subject medical r ecords, hospi[INVESTIGATOR_1332], clinic charts, 
investigator subject study file s, as well as the results of diagnostic tests (e.g., laboratory 
tests, visual fiel d test printouts). 
 
The following minimum information should be  entered into the subject's medical 
record: 
‐ The date the subject entered th e study and the subject number 
‐ The study protocol number and the name [CONTACT_11276] 
‐ The date that informed consent was obtained 
‐ Evidence that the subject meets study eligibility requirements (e.g., medical 
history, study procedures  and/or evaluations) 
‐ The dates of all study related subject visits 
‐ Evidence that required procedures and/or evaluations were completed 
‐ Use of any concurrent medications 
‐ Documentation of study medication acc ountability, including a copy of study 
medication labels 
‐ Occurrence and status of  any adverse events 
‐ The date the subject exited the study, a nd a notation as to whether the subject 
completed the study or was discon tinued, including the reason for 
discontinuation 
   
16.2.  Data Collection  
The clinical investigator must maintain detaile d records on all enrolled subjects.  Data for 
enrolled subjects will be collected with an el ectronic data capture system. The electronic 
database, which is Title 21 CFR Part 11 compliant, will be managed by a data management vendor. Access to the database w ill be granted to authorize study personnel 
based on their role after training; and the access will be password-protected. The data clarification process will be ma naged within the electronic data capture system by [CONTACT_152599]-generated or manually generated elect ronic queries. Accuracy of data will be 
verified by 100% source data ve rification at regular intervals,  and all corrections to data 
will be made in the database. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 56 of 91 
 
Exit forms are completed for all enrolled subjec ts, regardless of their final study status 
(e.g., subject discontinuation, study termination). 
 
16.3.  Study Supply Accountability 
The principal investigator [INVESTIGATOR_152592] r ensuring that an inventory is conducted upon 
receipt of the clinical supplies and that the clinical study supplies are received and stored 
as instructed. The receipt of clinical supplie s should be completed, signed, and returned 
as directed by [CONTACT_11268] (or designee). A copy must be maintained at the site for the 
investigator's records. The principal invest igator will keep a current record of the 
inventory and dispensing of all study medicati ons. This record will be made available to 
the Glaukos monitor (or designee) for the purpo se of accounting for all clinical supplies. 
Any significant discrepancy and/or deficiency must be record ed with an explanation. All 
supplies sent to the investigator must  be accounted for and in no case will study 
medications be used in any unauthorized situation. 
 It is the responsibility of the principal investigator [INVESTIGATOR_152593] (or designee)  at the conclusion of the study. 
 
16.4.  Record Retention 
All records relating to the conduct of this study are to be retained by [CONTACT_152600].  The investigator will allow re presentatives of Glaukos' m onitoring team (or designee), 
the governing institutional re view board, the Food and Drug Administration (FDA), and 
other applicable regulatory agencies to  inspect all study records, CRFs, and 
corresponding portions of the s ubject's office and/or hospi[INVESTIGATOR_152594]. These inspecti ons are for the purpose of verifying 
adherence to the protocol, completeness, and exactness of the data being entered onto the 
CRF, and compliance with FDA or ot her regulatory agency regulations. 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 58 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 59 of 91 
  
19. APPENDIX B - OBLIGATIONS OF INVESTIGATORS 
 
In summary, the clinical investigator has agreed to the following obligations: 
‐ Obtaining informed consent from ever y subject prior to enrollment in the 
study and maintaining records of cons ent as part of the study records. 
‐ Obtaining approval from the Institu tional Review Board (IRB) before 
enrolling any subject; submitting verificat ion of the approval to the Sponsor; 
submitting periodic progress reports (at least annually) and final report to IRB. 
‐ Approving the protocol and conducting th e study according to the protocol 
and applicable regulations; informing the Sponsor of all deviations from the protocol. 
‐ Informing the IRB of all protocol amendments/modifications; sending the 
Sponsor a copy of the letter from the IRB approving the amendment/modification. 
‐ Reporting to the Sponsor and the IRB a ny adverse experiences that occur in 
the course of the investigation. 
‐ Keepi[INVESTIGATOR_11250] (study records 
must be considerably more exact and co mplete than those kept in ordinary 
medical practice); maintaining records of all materials submitted to the IRB 
and of all action by [CONTACT_11270]. 
‐ Making study records available for in spection by [CONTACT_456] (Glaukos) and 
representatives of the Food and Drug Administration; keepi[INVESTIGATOR_152595]. 
‐ Maintaining proper control and documentation of all test and control articles. 
‐ Submitting the following records and repor ting to the Sponsor (See I, II, and 
III). 
 
I. Prior to the Beginning of the Study 
‐ A signed Form FDA-1572 or Statement of Investigator. 
‐ A current curriculum vitae (CV) if not  submitted to Glaukos previously or 
if updated. 
‐ CVs for all sub-investigators listed on the 1572. 
‐ A letter from the Institutional Review Board (IRB) indicating that the protocol was approved, including th e name [CONTACT_11277]. 
‐ A copy of the consent form approved by [CONTACT_1744]. 
‐ A list of current members of the IRB. 
 
II. While the Study is in Progress 
‐ Acknowledgment of receipt of the test and control articles; documentation of disposition of all te st and control articles. 
‐ Original Case Report Forms for each subject enrolled in the study. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 60 of 91 
‐ Information regarding all devi ations from the protocol. 
‐ Information regarding all adverse medi cal events occurring to a subject 
while enrolled in the study. 
‐ Annual progress report (if study is ongoing for more than one year). Letter 
from the IRB indicating approval of the annual progress report. 
 
III. Once the Study is Completed 
‐ Disposition of all used and/or unused test and control ar ticles, as well as 
documentation of all drug accountability. 
‐ A final study report (if requested). 
 20. APPENDIX C - ELEMENTS OF INFORMED CONSENT 
I. Elements of Informed Consent The following information must be pr ovided to each subject in obtaining 
informed consent. If written consent is being obtained, the subject (or subject's 
legal representative) should be provid ed with a copy of the signed written 
informed consent. 
 
1. State that the study involves RESEARCH. 
 
A. Explain the PURPOSE of the research. 
B. State the expected DURATION of the subject's participation. 
C. Describe the PROCEDURES to be followed. 
D. Identify any EXPERIMENTAL procedures. 
 
2. Describe any reasonably foreseeable RI SKS OR DISCOMFORTS to the subject. 
 
3. Describe any BENEFITS to the subject or to others that  may reasonably be 
expected from the research. 
 
4. Note appropriate ALTERNATIVE procedures or courses of  treatment, if any that 
might be advantageous to the subject. 
 
5. a. Describe the extent, if any, to  which CONFIDENTIALITY of records 
identifying the subject will be maintained. 
b. Note that the Food and Drug Admini stration MAY INSPECT the records. 
 
6. For research involving more than mini mal risk, explain if any COMPENSATION 
or medical treatments are available should injury occur. If so, explain (a) what 
they consist of, OR (b) where furt her information may be obtained. 
 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175733] for ANSWERS to pertinent questi ons about (a) the 
research, and (b) resear ch subjects’ rights. 
b. Tell whom to contact [CONTACT_44751]  a research-related INJURY to the 
subject. 
 
8. State that: 
a. Participation is VOLUNTARY, 
b. Refusal to participate will involve NO PENALTY or loss of benefits to 
which the subject is otherwise entitled, and 
c. The subject MAY DISCONTINUE particip ation at any time without penalty 
or loss of benefits to which the subject is otherwise entitled. 
 
II. Additional Elements of Informed Consent 
 When appropriate, one or more of the followi ng elements of information shall also be 
provided to each subject:  
1. A statement that particular treatment or procedure may involve risks to the 
subject (or to the embryo or fetus, if the subject is or may become pregnant) 
which are currently unforeseeable. 
2. Anticipated circumstances under which the subject's participation may be 
terminated by [CONTACT_152601] t regard to the subject's consent. 
3. Any additional costs to the subject that may result from participation in the research. 
4. The consequences of a subject's decisi on to withdraw from  the research and 
procedures for orderly termination of participation by [CONTACT_423]. 
5. A statement that significant new findings  developed during the course of the 
research, which may relate to the subject's  willingness to continue participation, 
will be provided to the subject. 
6. The approximate number of s ubjects involved in the study. 
 The informed consent requirements in these regulations are not intended to preempt any 
applicable Federal, State, or local laws which require additional information to be 
disclosed for informed consent to be legally effective.  
Nothing in these regulations is intended to limit the authority of a physician to provide 
emergency medical care to the extent the physician is permitted to do so under applicable 
Federal, State, or local law.  REFERENCE: 21 CFR Part 50.25 - PROTECTION OF HUMAN SUBJECTS, Elements of informed consent. 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175734] the health of the 
people. The physician’s knowledge and conscience are dedicated to the 
fulfillment of this duty. 
3. The Declaration of Geneva of the World Medical Association binds the 
physician with the words, "The health  of my patient will be my first 
consideration," and the International Code of Medical Ethics declares that, "A 
physician shall act only in the patient's interest when providing medical care 
which might have the effect of weakening the physical and mental condition 
of the patient." 
4. Medical progress is based on research wh ich ultimately must rest in part on 
experimentation involv ing human subjects. 
5. In medical research on human subjects, considerations related to the well-
being of the human subject should ta ke precedence over the interests of 
science and society. 
6. The primary purpose of medical resear ch involving human subjects is to 
improve prophylactic, diagnostic and therapeutic pro cedures and the 
understanding of the aetiology and pathoge nesis of disease. Even the best 
proven prophylactic, diagnos tic, and therapeutic met hods must continuously 
be challenged through research  for their effectiveness, efficiency, accessibility 
and quality. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175735] and 
incentives for subjects. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175736], the confidentiality of the patient’s information and to minimize the 
impact of the study on the subject's phys ical and mental integrity and on the 
personality of the subject. 
13. In any research on human beings, each potential subject must be adequately 
informed of the aims, methods, source s of funding, any possi ble conflicts of 
interest, institutional affiliations of the researcher, the anticipated benefits and 
potential risks of the study and the discomfort it may entail. The subject 
should be informed of the right to abstain from partic ipation in the study or to 
withdraw consent to participate at an y time without reprisal. After ensuring 
that the subject has understood the in formation, the physician should then 
obtain the subject's freely given informed consent, preferably in writing. If the 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175737] 
obtain that assent in addition to th e consent of the le gally authorized 
representative. 
17. Research on individuals from whom it is not possible to obtain consent, 
including proxy or advance consen t, should be done only if the 
physical/mental condition that prevents  obtaining informed consent is a 
necessary characteristic of the research population. The specific reasons for 
involving research subjects with a cond ition that renders them unable to give 
informed consent should be stated in the experimental protocol for 
consideration and approval of the review  committee. The protocol should state 
that consent to remain in the research should be obtained as soon as possible 
from the individual or a le gally authorized surrogate. 
18. Both authors and publishers have ethi cal obligations. In publication of the 
results of research, the investigators are obliged to preserve the accuracy of 
the results. Negative as well as positive results should be published or 
otherwise publicly available. Sources of  funding, institutional affiliations and 
any possible conflicts of interest s hould be declared in the publication. 
Reports of experimentation not in accord ance with the principles laid down in 
this Declaration should not be accepted for publication. 
 
 
 
 
 
 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175738] be free to use unproven or new 
prophylactic, diagnostic and therapeutic measures, if in the physician’s 
judgment it offers hope of saving life, re-establishing health  or alleviating 
suffering. Where possible, these measures should be made the object of 
research, designed to eval uate their safety and e fficacy. In all cases, new 
information should be recorded and, wh ere appropriate, published. The other 
relevant guidelines of this Declaration should be followed. 
 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 67 of 91 
22. APPENDIX E – GLA[LOCATION_006]OS TRAVOPROST INTRAOCULAR IMPLANT 
SURGICAL INSTRUCTIONS 
 
Do not use the implant if the Tyvek lid on the blister tray has been opened or the 
packaging appears damaged.  In such cases, the sterility of the implants may be 
compromised.  
Surgical Instructions 
1. The eye should be anesthetized using general, retrobulbar, peribulbar, or 
topi[INVESTIGATOR_152596]. 
2. It is recommended that the implant surg ery be performed from the temporal 
side, using a temporal clear corneal incision, to provide clear access for the 
surgical instruments.  The implant w ill be implanted through the trabecular 
meshwork on the nasal side.  
3. Create a clear corneal incision at the temporal limbus location using an 
instrument of the surgeon’s choice. 
4. A cohesive viscoelastic is added to the anterior chamber as needed to improve 
visualization of the angle, and to ma intain IOP for use of the gonioscope.  
5. A gonioscope is placed on the cornea and the surgical microscope and the patient are positioned as needed to visualize the angle, through the gonioprism, on the nasal side of the eye.  Tilting the patient’s head as far as 
practical away from the surgeon, and also tilting the microscope toward the surgeon will help viewing of the angle. 
6. The angle is inspected using a gonioprism  to ensure good visualization at the 
nasal implant location.   
7. Remove the G2TR  or G2TR- on its inserter from the blister tray. Inspect the implant on the tip of the inserter. 
8. When ready for implantation, remove safety clip which holds trigger in place. Keep finger on trigger button to ensure it remains in the forward position and 
doesn’t prematurely release implant. 
9. Insertion of Model G2TR-  or G2TR-   
a. Deepen the anterior chamber with additional viscoelastic to aid in 
chamber maintenance as needed. 
b. Enter the anterior chamber with th e implant using supplied inserter. 
c. Advance to the pupi[INVESTIGATOR_152597]. 
d. Care must be taken to avoid contact [CONTACT_152602]. 
e. Advance to the anterior chamber angle and approach the trabecular meshwork.   
f. Press the distal end of the implant directly into an d through trabecular 
meshwork until the barb at the tip securely penetrates the sclera at the outer wall of Schlemm’s canal, a nd the base of the cylindrical 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, [ADDRESS_175739] from the implant with out allowing it to pull the implant 
of position. 
i. Withdraw the insertion in strument from the eye. 
 
10. High-magnification examination is performed to confirm that the implant is in 
proper position (i.e., the proximal end rest s in the anterior chamber with an 
unobstructed membrane) and securely atta ched with the tip barb thoroughly 
embedded in sclera. 
11. It is normal for an edge of the implant to make contact [CONTACT_152603], but most of 
the membrane should be unobstructed by [CONTACT_152604]. 
12. The anterior chamber is irrigated and aspi[INVESTIGATOR_152598] (BSS) through the corneal wound to rem ove all viscoelastic.  The surgeon 
may press down on the posterior edge of the incision as needed to facilitate 
complete removal of viscoelastic. 
13. The anterior chamber is inflated with saline solution as needed to achieve physiologic pressure. 
 Do not use the implant if the Tyvek lid on the blister tray has been opened or the 
packaging appears damaged.  In such cases, the sterility of the implants may be compromised.   
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 77 of 91 
 

 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 78 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 79 of 91 
24. APPENDIX G – ARTIFICIAL TEARS PACKAGE INSERT 
 
 
 
 
col No.: 
09 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 81 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 83 of 91 
25. APPENDIX H – ASSIGNING SUBJECT NUMBERS AND KITS  
Subject and kit numbers will be dispensed using in accordance with detailed instructions provided separate ly. The investigator or his/ her designee must access the 
electronic data base to obtain detail s of subject randomi zation and kit use. 
    
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 91 of 91 
baseline, Week 1-2 (10 day ± 3), Week [ADDRESS_175740] at a lab in close proximity to the investigational site. 
 
 